🔎 Trials Near Me

Beranda › Kanker Metastatik › Georgia › Atlanta

Uji klinis Kanker Metastatik di Atlanta, GA

28 studi untuk Kanker Metastatik mencari peserta di lokasi sekitar Atlanta (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Menerima pesertaFase 3
  • Piedmont Cancer Institute, Atlanta
  • Piedmont Healthcare, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT07562152

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1
  • Winship Cancer Institute of Emory University, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06270706

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Menerima pesertaFase 1
  • Emory University, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06465069

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Menerima pesertaFase 1
  • Emory Winship Cancer Institute, Atlanta
Usia 19 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06586957

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Menerima pesertaFase 1/2
  • Children's Healthcare of Atlanta - Egleston Hospital, Atlanta
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04094610

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

Menerima pesertaFase 1
  • Emory Winship Cancer Institute, Atlanta
Usia 18 ke atas · Pria · Diperbarui 24 Sep 2026 · NCT07543055

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Menerima pesertaFase 1
  • Emory University School of Medicine - Winship Cancer Institute, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07114601

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Menerima pesertaFase 3
  • Winship Cancer Institute, Emory University, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213804

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Menerima pesertaFase 3
  • Emory University School of Medicine- Grady Campus, Atlanta
  • Winship Cancer Institute, Emory University, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Menerima pesertaFase 1
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT04585958

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Menerima pesertaFase 1/2
  • Avenzo Therapeutics Recruiting Site, Atlanta
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07038343

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Menerima pesertaFase 3
  • Winship Cancer Institute of Emory University, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06072612

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 2
  • Emory University School of Medicine, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06769698

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

Menerima pesertaFase 1
  • Emory University Hospital, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT05614739

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Menerima pesertaFase 1/2
  • Crinetics Study Site, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07129252

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Menerima pesertaFase 1
  • Winship Cancer Center - Emory University, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT06657144

A Study of PYX-201 in Advanced Solid Tumors

Menerima pesertaFase 1
  • Winship Cancer Institute, Emory University, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT05720117

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Menerima pesertaFase 1/2
  • Winship Cancer Institute, Emory University, Atlanta
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT05384626

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Menerima pesertaFase 1
  • Winship Cancer Institute at Emory University, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT07094204

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Menerima pesertaFase 1/2
  • Piedmont Healthcare, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Mei 2026 · NCT05379985

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 3
  • Emory University, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06064877

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Menerima pesertaFase 2/3
  • Emory Winship Cancer Institute, Atlanta
Semua usia · Semua jenis kelamin · Diperbarui 2 Apr 2026 · NCT06581406

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Menerima pesertaFase 1/2
  • Emory Winship Cancer Institute, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Apr 2026 · NCT05735080

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Menerima pesertaFase 1
  • Children's Healthcare of Atlanta at Arthur M. Blank Hospital, Atlanta
Usia 1 hingga 40 · Semua jenis kelamin · Diperbarui 12 Mar 2026 · NCT05292664

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Menerima pesertaFase 3
  • Emory Winship Cancer Institute, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Feb 2026 · NCT06127407

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Menerima pesertaStudi observasional
  • Massive Bio SYNERGY-AI site, Atlanta
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

Menerima pesertaFase awal 1
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2025 · NCT06328686

A Beta-only IL-2 ImmunoTherapY Study

Menerima pesertaFase 1/2
  • Emory - Winship Cancer Institute, Atlanta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2025 · NCT05086692

Uji klinis Kanker Metastatik di kota lain

Studi lain di Atlanta

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.